We have designed MT‐7117 (dersimelagon phosphoric acid), a novel oral MC1R agonist that is currently in development as a photoprotective agent for patients with EPP and X‐linked protoporphyria (XLP). This evidence concerns the gene MC1R and autosomal erythropoietic protoporphyria.